Domača stranFLNA • NASDAQ
add
Filana Therapeutics Inc
1,56 $
Po zaprtju:(2,56 %)+0,040
1,60 $
Konec trgovanja: 27. apr., 17:39:12 GMT -4 · USD · NASDAQ · Izjava
Prejšnji trg. dan.
1,61 $
Dnevni razpon
1,56 $ - 1,63 $
Letni razpon
1,54 $ - 2,27 $
Tržna kapitalizacija
75,35 mio. USD
Povprečni obseg
407,12 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | dec. 2025info | Sprememba L/L |
|---|---|---|
Prihodek | — | — |
Stroški poslovanja | 5,70 mio. | −36,37 % |
Čisti dohodek | −12,54 mio. | 54,56 % |
Čista dobičkovnost prihodkov | — | — |
Earnings per share | — | — |
EBITDA | −9,18 mio. | 68,57 % |
Efektivna davčna stopnja | — | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | dec. 2025info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 95,50 mio. | −25,72 % |
Skupna sredstva | 118,36 mio. | −24,87 % |
Skupne obveznosti | 43,95 mio. | 271,56 % |
Celoten lastniški kapital | 74,40 mio. | — |
Shares outstanding | 48,31 mio. | — |
Razmerje P/B | 1,05 | — |
Donosnost sredstev | −19,25 % | — |
Donosnost kapitala | −30,62 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | dec. 2025info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −12,54 mio. | 54,56 % |
Denar iz dejavnosti | −9,75 mio. | 84,09 % |
Denar iz naložb | −501,00 tis. | −778,95 % |
Denar iz financiranja | −329,00 tis. | −135,84 % |
Neto sprememba denarnih sredstev | −10,58 mio. | 82,49 % |
Prost denarni tok | −4,32 mio. | 64,46 % |
Vizitka
Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. The company was developing simufilam, an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
In June 2024, the United States Department of Justice charged an advisor to company, Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was the company's senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Barbier, Burns and Wang. The parties did not admit wrongdoing, but agreed to pay fines of the company $40 million, Barbier $175,000, Burns $85,000, and Wang $50,000. The DOJ dropped the fraud charges against Wang shortly before trial was scheduled to begin in October 2025 without giving a reason. Wikipedia
Datum ustanovitve
1998
Sedež organizacije
Zaposleni
19
